Horizon Europe project geneTIGA begins this July
The project within the Horizon Europe grant starts this July. The prevalence of chronic diseases caused by unwanted immune reactions is increasing (>10%) and places a heavy burden on both patients (chronicity, organ failure, premature death, reduced quality of life) and society, as current therapies are limiting in their efficacy and do not sustainably re-shape the disturbed immune balance. The ultimate goal of the project is to develop a safe and efficient cell therapy based on genomically edited T cells with redirected specificity to sustainably combat IgA nephropathy (IgAN), the most common glomerulonephritis and one of the most frequent causes of end-stage renal disease with unmet medical needs. Our targeted cell therapy approach is also suitable for other diseases with selective B-cell pathogenesis, such as IgA myeloma, IgA-related celiac disease and rheumatoid arthritis, but also for other diseases with selective B-cell pathogenesis. rheumatoid arthritis, but also for diseases of other Ig classes (e.g. IgG4).
